文章：

多组学视角下揭示泛癌中RNA修饰调控因子的临床全景

Unraveling the Clinical Landscape of RNA Modification Regulators with Multi-Omics Insights in Pan-Cancer

原文发布日期：19 August 2025

DOI: 10.3390/cancers17162695

类型: Article

开放获取: 是

英文摘要：

Background/Objectives:Cancer remains a major global health challenge, with RNA modifications increasingly recognized as key regulators of tumor progression. However, integrated pan-cancer analyses across multiple modification types are limited.Methods:We performed a comprehensive analysis of 170 RNA modification-related genes across 33 cancer types, uncovering diverse expression, mutation, and epigenetic patterns.Results:Key regulators such asIGF2BP3,CFI, andELF3showed cancer-specific prognostic significance. We developed an RNA Modification Score (RMS) with strong prognostic performance (AUC up to 0.92), correlating with the tumor stage, immune infiltration, and immunotherapy response. High-risk groups exhibited immune checkpoint dysregulation and enriched M1 macrophages in glioblastoma. Drug screening highlighted oncrasin-72 as a potential therapy. Validation via single-cell/spatial transcriptomics and immunohistochemistry confirmed the spatial localization of critical genes likeCFIandELF3.Conclusions:Our study reveals the multifaceted role of RNA modifications in cancer, providing a translational framework for personalized prognosis and therapy in precision oncology.

摘要翻译： 

**背景/目的：** 癌症仍是全球重大健康挑战，RNA修饰作为肿瘤进展的关键调控因子日益受到关注。然而，针对多种修饰类型的综合性泛癌分析仍较为有限。 **方法：** 我们对33种癌症类型中的170个RNA修饰相关基因进行了全面分析，揭示了其表达、突变及表观遗传模式的多样性。 **结果：** 关键调控因子如IGF2BP3、CFI和ELF3显示出癌症特异性的预后意义。我们构建了RNA修饰评分（RMS），其具有强大的预后预测能力（AUC最高达0.92），并与肿瘤分期、免疫浸润及免疫治疗反应相关。高风险组在胶质母细胞瘤中表现出免疫检查点失调和M1巨噬细胞富集。药物筛选提示oncrasin-72可能具有治疗潜力。通过单细胞/空间转录组学及免疫组化验证，确认了CFI和ELF3等关键基因的空间定位特征。 **结论：** 本研究揭示了RNA修饰在癌症中的多层面作用，为精准肿瘤学中的个体化预后评估与治疗提供了转化框架。

原文链接：

Unraveling the Clinical Landscape of RNA Modification Regulators with Multi-Omics Insights in Pan-Cancer